GSK begins phase 3 trial for otilimab in patients with rheumatoid arthritis

This article was originally published here

The progression of otilimab (previously GSK3196165) into phase III follows the results of the phase II BAROQUE study which were announced in October 2018. Dr Hal Barron, Chief

The post GSK begins phase 3 trial for otilimab in patients with rheumatoid arthritis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply